Report Overview

The U.S. Anti-depressant drugs market size stood at USD 4.51 billion 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

The U.S. depression drugs market is expected to grow at a CAGR of 2.5% during 2019-2024. Depression drugs, or antidepressants, are a range of medications that are consumed for the treatment of mental disorders such as social anxiety and depression. They are intended to balance the functioning of neurotransmitters such as serotonin in the brain, thus controlling the mood and emotions of the patient. Depression and related mental disorders are characterized by the absence of positive emotions, constant low mood, and numerous cognitive, physical, behavioural, and emotional symptoms. These drugs can assist in relieving the symptoms of anxiety, seasonal affective disorder, and dysthymia

Antidepressant medications include the use of Selective Serotonin Reuptake Inhibitors (SSRIs), atypical antidepressants and Monoamine Oxidase Inhibitors (MAOIs) that are most effective when consumed along with regular therapeutic sessions



Market Drivers

The growing prevalence of major depressive disorders across U.S. is the key factor driving the growth of the market. Depression in adolescents and adults is increasing due to several factors including social isolation, improper dietary habits, and work-life imbalance. Furthermore, the increasing geriatric population across the U.S. that suffers from isolation from family and friends, along with other health-related issues, are also augmenting the growth of the market. However, there is rising awareness about depression as a psychological issue and methodologies to cure it, which has enhanced the adoption of these drugs among patients of all age groups. Additionally, the emergence of novel techniques for the development of antidepressants with minimal side-effects and prolonged results, along with the acceptance of new medications, is also favouring the market growth